Menu
GeneBe

M-7445-A-G

Variant summary

Our verdict is Likely pathogenic. Variant got 9 ACMG points: 10P and 1B. PM2PP5_Very_StrongBP7

The ENST00000361624.2(MT-CO1):c.1542A>G(p.Ter514=) variant causes a stop retained change involving the alteration of a non-conserved nucleotide. Variant has been reported in ClinVar as Pathogenic (★★★).

Frequency

Mitomap GenBank:
Absent

Consequence

MT-CO1
ENST00000361624.2 stop_retained

Scores

Clinical Significance

Pathogenic reviewed by expert panel P:5O:1
DEAF,SNHL,SNHL

Conservation

PhyloP100: -0.943
Variant links:
Genes affected
MT-CO1 (HGNC:7419): (mitochondrially encoded cytochrome c oxidase I) Contributes to cytochrome-c oxidase activity. Predicted to be involved in electron transport coupled proton transport and mitochondrial electron transport, cytochrome c to oxygen. Part of mitochondrial respiratory chain complex III and mitochondrial respiratory chain complex IV. [provided by Alliance of Genome Resources, Apr 2022]
MT-TS1 (HGNC:7497): (mitochondrially encoded tRNA serine 1 (UCN))

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_pathogenic. Variant got 9 ACMG points.

PM2
No frequency data in Mitomap. Probably very rare.
PP5
Variant M-7445-A-G is Pathogenic according to our data. Variant chrM-7445-A-G is described in ClinVar as [Pathogenic]. Clinvar id is 9563.Status of the report is reviewed_by_expert_panel, 3 stars.
BP7
Synonymous conserved (PhyloP=-0.943 with no splicing effect.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
COX1COX1.1 use as main transcriptc.1542A>G p.Ter514= stop_retained_variant 1/1
TRNS1TRNS1.1 use as main transcript downstream_gene_variant

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
MT-CO1ENST00000361624.2 linkuse as main transcriptc.1542A>G p.Ter514= stop_retained_variant 1/1 P1
MT-TS1ENST00000387416.2 linkuse as main transcript downstream_gene_variant

Frequencies

GnomAD4 exome
Cov.:
0
We have no GnomAD4 genomes data on this position. Probably position not covered by the project.
Gnomad homoplasmic
AF:
0.0
AC:
0
AN:
56432
Gnomad heteroplasmic
AF:
0.000035
AC:
2
AN:
56432

Mitomap

DEAF,SNHL,SNHL

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:5Other:1
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Mitochondrial non-syndromic sensorineural hearing loss Pathogenic:2Other:1
not provided, no classification providedliterature onlyGeneReviews-- -
Pathogenic, no assertion criteria providedliterature onlyOMIMJan 01, 2001- -
Pathogenic, criteria provided, single submitterclinical testingMendelicsMay 04, 2022- -
Palmoplantar keratoderma-deafness syndrome Pathogenic:1
Pathogenic, no assertion criteria providedliterature onlyOMIMJan 01, 2001- -
Mitochondrial disease Pathogenic:1
Pathogenic, reviewed by expert panelcurationClinGen Mitochondrial Disease Nuclear and Mitochondrial Variant Curation Expert Panel, ClinGenAug 08, 2022The m.7445A>G variant is located in the MT-TS1 precursor, overlapping with MT-CO1 (Term514Term). This variant has been reported in at least 32 individuals with primary mitochondrial disease, and the only consistent reported feature in affected individuals was hearing loss (PS4; PMIDs: 8019558, 8572257, 9450881, 11069477, 11175301, 15620132, 16092542, 15987292, 23525847, 18537605, 22567359, 21621438, 30035268, 26328603, 29605341, 32169613). Some individuals with this variant have normal hearing, others have hearing loss following aminoglycoside exposure, and others have hearing loss and no known aminoglycoside exposure. The age of onset ranges from infancy to adulthood. The variant is primarily seen in the homoplasmic state however some individuals were reported to have low heteroplasmy levels in blood. Several extended families have been reported in the medical literature however family member testing was not performed or the variant was homoplasmic and thus prevented consideration for segregation evidence of pathogenicity. There are no reports of de novo occurrences in the medical literature to our knowledge however the presence of this variant in individuals from different haplogroups suggests this variant occurred de novo in the ancestors of these individuals of different backgrounds. Of note, another 137 elderly individuals were found to carry this variant in platelets with heteroplasmy levels >2%, and this was reported to significantly correlate with high frequency hearing loss (PMID: 26328603), however these cases were excluded from this curation given the lack of other clinical details. There is one occurrence of this variant in the Mitomap GenBank dataset, however this is from an individual with known mitochondrial disease. This variant is absent in gnomAD v3.1.2. There are six heteroplasmic occurrences in the Helix dataset. Although there are several occurrences, the frequency is still low (PM2_supporting). There are no in silico predictors for this type of variant in mitochondrial DNA. Cybrid studies supported the functional impact of this variant (PS3_supporting). One study showed a 60-70% reduction of steady state ND6 levels and 40-50% reduction of tRNASer (PMID: 15694374). Other cell line studies showed significantly reduced Complex I activity, with lesser reduction in Complex IV (P=0.05; PMID 29934116). Of note, there is one early cell line study that did not demonstrate any bioenergetic impact of this variant (PMID: 9247714). In summary, this variant meets criteria to be classified as likely pathogenic however this Expert Panel elected to modify the classification to pathogenic given the extent of cases with similar phenotypes from different ethnic backgrounds that have been reported, that is further supported by the evidence outlined above. Furthermore, the mitochondrial DNA variant specifications are known to not be optimized for variants that tend to be homoplasmic in nature and/or have reduced penetrance, such as the common mitochondrial variants associated with nonsyndromic hearing loss. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on August 8, 2022. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PS4, PM2_supporting, PS3_supporting. -
Juvenile myopathy, encephalopathy, lactic acidosis AND stroke Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingWong Mito Lab, Molecular and Human Genetics, Baylor College of MedicineJul 12, 2019The NC_012920.1:m.7445A>G variant in MT-TS1 gene is interpreted to be a Pathogenic variant based on the modified ACMG guidelines (unpublished). This variant meets the following evidence codes reported in the guidelines: PS3, PS5 -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction

Splicing

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs199474818; hg19: chrM-7446; API